The MOU, which will formalise a bilateral cooperation in biomedical fields, was signed by IBMI VP Pang-Chyr Yang and Chief Executive Charles Li at Hong Kong Exchanges and Clearing Limited (HKEX) during the IBMI delegation's visit to HKEX Biotech Summit.
In a closed-door meeting with Li, the delegates, including VP Pan-Chyr Yang and CEO Allen Wu at IBMI, Chairman Howard Lee at Easywell Biomedicals (易威生醫李世仁董事長) and President CY Huang at FCCP (藍濤亞洲黃齊元總裁), came with suggestions for biotech companies’ public listing and incorporation of TFDA in phase II clinical trial regulatory authorities.
IBMI and HKEX looked to channel the capital and global funding source Hong Kong has into Taiwan’s biomedical strength areas, facilitate product launch through joint ventures and investments and enhance the global presence of Taiwan-Hong Kong biomedical industry alliance. Yang said in a interview that he was looking forward to seeing Taiwan-based biotech companies go public listing with KHEX. “Hong Kong provides a free and international fund-raising environment, where it is indeed an indispensable partner to Taiwan in terms of R&D, product and industry development.”
James C. Greenwood, President & CEO of Biotechnology Innovation Organization (BIO), addressed at HKEX Biotech Summit with the topic regarding global trends and development of biotechnology. VP Yang at IBMI introduced the Healthcare+ Expo Taiwan to Mr Greenwood during their meeting and received a positive response to BIO’s participation in the future.
From left to right: Dr Por Lai (Founder, A-Spine Asia), Pang-Chyr Yang (VP, IBMI), James Greenwood (President & CEO, BIO), Allen Wu (CEO, IBMI)